Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicentre, Randomised, Parallel-arm, Placebo-controlled, Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

NCT06925061 is registered in ClinicalTrials.gov with Madeleine Bezault as lead sponsor.

NCT NCT06925061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06925061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicentre, Randomised, Parallel-arm, Placebo-controlled, Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease
Lead sponsor
Madeleine Bezault
Phase
Phase 2
Overall status
Recruiting
Start date
March 31, 2025
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd)